ArticleBMC cardiovascular disorders2025
Preoperative hemoglobin predicts clinical outcomes after percutaneous coronary intervention.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcurrent anemia is associated with an increased risk of major adverse cardiac events (MACE) in patients with myocardial infarction. The study aimed to assess the value of anemia and preoperative hemoglobin levels in predicting clinical outcomes in stable coronary artery disease (SCAD) patients receiving percutaneous coronary intervention (PCI).
methodsThis is a secondary analysis based on a retrospective cohort study in which 204 patients with SCAD who received PCI were recruited. The primary outcome was major adverse cardiac events (MACE; including all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke) and the secondary outcome was cardiovascular events (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke).
resultsDuring a median follow-up of 783 days, MACE occurred in 28 patients. In multivariate COX regression analysis, after adjusting for potential confounding factors, low hemoglobin level independently predicted worse prognosis at the primary endpoint (HR = 0.72, 95% CI 0.56 to 0.93, p = 0.012) and the secondary endpoint (HR = 0.71, 95% CI 0.52 to 0.96, p = 0.027) after PCI. The receiver operating characteristic curve (ROC) showed that the best threshold for hemoglobin to predict MACE was 12.25 g/dl. In Kaplan-Meier analysis, hemoglobin < 12.25 g/dl predicted worse prognosis in MACE (p < 0.001).
conclusionsLow preoperative hemoglobin level increased the risk of MACE in SCAD patients receiving PCI and the optimal threshold for predicting MACE is 12.25 g/dl.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.